PMID- 31595223
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2364-3722 (Print)
IS  - 2196-9736 (Electronic)
IS  - 2196-9736 (Linking)
VI  - 7
IP  - 10
DP  - 2019 Oct
TI  - Intraductal temperature-controlled radiofrequency ablation in malignant hilar 
      obstruction: a preliminary study in animals and initial human experience.
PG  - E1293-E1300
LID - 10.1055/a-0970-9005 [doi]
AB  - Background and study aims  Intraductal radiofrequency ablation (ID-RFA) is a 
      recently developed method widely used for treatment of malignant extrahepatic 
      biliary tract obstructions. However, its safety in hilar application has yet to 
      be clearly demonstrated. The aim of this study was to evaluate the safety of 
      ID-RFA in the treatment of malignant hilar obstruction. Patients and methods  
      Endoscopic retrograde cholangiography followed by temperature-controlled ID-RFA 
      at the hilar area using different probe lengths (11, 18, and 22 mm) and settings 
      (7 or 10 W for 60 - 120 s) was performed in six mini-pigs. In addition, patients 
      with malignant hilar obstruction who underwent palliative ID-RFA were 
      retrospectively evaluated. Results  In the animal study using different ID-RFA 
      settings , post-ID-RFA fluoroscopic radiocontrast leakage and microscopic bile 
      duct perforation with hepatic abscess were observed in four of the six mini-pigs. 
      Only two of the them, in which an 11-mm ID-RFA probe at a target temperature of 
      80  degrees C, power of 7 W, and duration of 60 s was used, underwent successful ID-RFA 
      without any immediate adverse events (AEs). Clinically, ID-RFA was performed 
      using the 11-mm probe with the setting of 80  degrees C, 7 W, and 60 - 120 s for 
      malignant hilar obstruction, and total of 11 patients underwent successful ID-RFA 
      without AEs. Conclusions  Our study suggests that ID-RFA performed using a 
      short-length probe with settings of 80  degrees C, 7 W and 60 - 120 s is a safe and 
      feasible palliative treatment for malignant hilar obstruction.
FAU - Kim, Eui Joo
AU  - Kim EJ
AD  - Department of Internal Medicine, Gachon University College of Medicine, Gil 
      Medical Center, Incheon, Republic of Korea.
FAU - Cho, Jae Hee
AU  - Cho JH
AD  - Department of Internal Medicine, Gachon University College of Medicine, Gil 
      Medical Center, Incheon, Republic of Korea.
FAU - Kim, Yoon Jae
AU  - Kim YJ
AD  - Department of Internal Medicine, Gachon University College of Medicine, Gil 
      Medical Center, Incheon, Republic of Korea.
FAU - Lee, Tae Hoon
AU  - Lee TH
AD  - Department of Internal Medicine, Soonchunhyang University College of Medicine, 
      Cheonan Hospital, Cheonan, Republic of Korea.
FAU - Kim, Joon Mee
AU  - Kim JM
AD  - Department of Pathology, Inha University School of Medicine, Incheon, Republic of 
      Korea.
FAU - Jeong, Seok
AU  - Jeong S
AD  - Department of Gastroenterology and Hepatology, and the National Center of 
      Efficacy Evaluation for the Development of Health Products Targeting Digestive 
      Disorders (NCEED), Inha University School of Medicine, Incheon, Republic of 
      Korea.
FAU - Kim, Yeon Suk
AU  - Kim YS
AD  - Department of Internal Medicine, Gachon University College of Medicine, Gil 
      Medical Center, Incheon, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20191007
PL  - Germany
TA  - Endosc Int Open
JT  - Endoscopy international open
JID - 101639919
CIN - Endosc Int Open. 2019 Oct;7(10):E1301-E1302. PMID: 31599272
PMC - PMC6779589
COIS- Competing interests None
EDAT- 2019/10/09 06:00
MHDA- 2019/10/09 06:01
PMCR- 2019/10/01
CRDT- 2019/10/10 06:00
PHST- 2019/01/16 00:00 [received]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/10/10 06:00 [entrez]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2019/10/09 06:01 [medline]
PHST- 2019/10/01 00:00 [pmc-release]
AID - 10.1055/a-0970-9005 [doi]
PST - ppublish
SO  - Endosc Int Open. 2019 Oct;7(10):E1293-E1300. doi: 10.1055/a-0970-9005. Epub 2019 
      Oct 7.